Literature DB >> 9660248

Chicken interferon types I and II enhance synergistically the antiviral state and nitric oxide secretion.

M J Sekellick1, J W Lowenthal, T E O'Neil, P I Marcus.   

Abstract

This report shows that chicken type I and type II interferons (IFNs), like their mammalian counterparts, act synergistically such that a mixture of the two has much greater activity than that expected from the separate contribution of each type. The degree of antiviral synergy was measured by virus plaque reduction and cytopathic effect (CPE) inhibition in both primary and secondary chicken embryo cell cultures. Mixtures of the two Ch-IFNs produced antiviral effects 3-10 times greater than that expected from strict additivity of each IFN acting alone. At high concentrations of IFN mixtures there was a qualitative shift to an exponential IFN action does-response curve that revealed synergistic effects greater than 100-fold. Synergy resulted even with mixtures containing less than 1 U/ml of either type of Ch-IFN. The antiviral effects developed more rapidly with mixtures than when type I or II Ch-IFN was used alone. Mixtures of the two types of Ch-IFN synergistically potentiated nitric oxide secretion in cells of the HD11 chicken macrophage line. Molecular mechanisms are cited that may account for synergy between type I and type II IFNs, and speculation is offered on the epidemiologic and therapeutic implications of synergy in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9660248     DOI: 10.1089/jir.1998.18.407

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  8 in total

1.  Possible involvement of the double-stranded RNA-binding core protein sigmaA in the resistance of avian reovirus to interferon.

Authors:  J Martínez-Costas; C González-López; V N Vakharia; J Benavente
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Expression of cytokine genes in Marek's disease virus-infected chickens and chicken embryo fibroblast cultures.

Authors:  Z Xing; K A Schat
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

3.  Buggy Creek virus (Togaviridae: Alphavirus) upregulates expression of pattern recognition receptors and interferons in House Sparrows (Passer domesticus).

Authors:  Carol A Fassbinder-Orth; Virginia A Barak; Ellecia L Rainwater; Ashley M Altrichter
Journal:  Vector Borne Zoonotic Dis       Date:  2014-05-27       Impact factor: 2.133

4.  Synergistic inhibition of SARS-coronavirus replication by type I and type II IFN.

Authors:  Eric C Mossel; Bruno Sainz; Robert F Garry; C J Peters
Journal:  Adv Exp Med Biol       Date:  2006       Impact factor: 2.622

5.  Amelioration of influenza virus pathogenesis in chickens attributed to the enhanced interferon-inducing capacity of a virus with a truncated NS1 gene.

Authors:  Angela N Cauthen; David E Swayne; Margaret J Sekellick; Philip I Marcus; David L Suarez
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

6.  In Ovo Administration of CpG ODN Induces Expression of Immune Response Genes in Neonatal Chicken Spleen.

Authors:  Joanna Sajewicz-Krukowska; Monika Olszewska-Tomczyk; Katarzyna Domańska-Blicharz
Journal:  J Vet Res       Date:  2017-12-27       Impact factor: 1.744

7.  Synthetic CpG-ODN rapidly enriches immune compartments in neonatal chicks to induce protective immunity against bacterial infections.

Authors:  Thushari Gunawardana; Khawaja Ashfaque Ahmed; Kalhari Goonewardene; Shelly Popowich; Shanika Kurukulasuriya; Ruwani Karunarathna; Ashish Gupta; Betty Lockerbie; Marianna Foldvari; Suresh K Tikoo; Philip Willson; Susantha Gomis
Journal:  Sci Rep       Date:  2019-01-23       Impact factor: 4.379

8.  A construction strategy for a baculovirus-silkworm multigene expression system and its application for coexpression of type I and type II interferons.

Authors:  Xingjian Liu; Xin Yang; Arslan Mehboob; Xiaoyuan Hu; Yongzhu Yi; Yinü Li; Zhifang Zhang
Journal:  Microbiologyopen       Date:  2019-12-19       Impact factor: 3.139

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.